title: Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings.
abstract: In regions where endemic measles virus has been eliminated, diagnostic assays are needed to assist in correctly classifying measles cases irrespective of vaccination status. A measles IgG avidity assay was configured using a commercially available measles-specific IgG enzyme immunoassay by modifying the protocol to include three 5-min washes with diethylamine (60 mM; pH 10.25) following serum incubation; serum was serially diluted, and the results were expressed as the end titer avidity index. Receiver operating characteristic analysis was used for evaluation and validation and to establish low (≤30%) and high (≥70%) end titer avidity thresholds. Analysis of 319 serum specimens expected to contain either high- or low-avidity antibodies according to clinical and epidemiological data indicated that the assay is highly accurate, with an area under the curve of 0.998 (95% confidence interval [CI], 0.978 to 1.000), sensitivity of 91.9% (95% CI, 83.2% to 97.0%), and specificity of 98.4% (95% CI, 91.6% to 100%). The assay is rapid (<2 h) and precise (standard deviation [SD], 4% to 7%). In 18 samples from an elimination setting outbreak, the assay identified 2 acute measles cases with low-avidity results; both were IgM-positive samples. Additionally, 11 patients (15 samples) with modified measles who were found to have high-avidity IgG results were classified as secondary vaccine failures; one sample with an intermediate-avidity result was not interpretable. In elimination settings, measles IgG avidity assays can complement existing diagnostic tools in confirming unvaccinated acute cases and, in conjunction with adequate clinical and epidemiologic investigation, aid in the classification of vaccine failure cases.
authors.affiliation: Centers For Disease Control and Prevention, Atlanta, Georgia, USA. sjm7@cdc.gov
authors.forename: Sara
authors.initials: S
authors.lastname: Mercader
authors.forename: Philip
authors.initials: P
authors.lastname: Garcia
authors.forename: William J
authors.initials: WJ
authors.lastname: Bellini
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D000915:Antibody Affinity; D060740:Disease Eradication; D006801:Humans; D007118:Immunoassay / Q000379:methods; D007074:Immunoglobulin G / Q000097:blood*; D007223:Infant; D008457:Measles / Q000175:diagnosis* / Q000276:immunology / Q000517:prevention & control*; D008458:Measles Vaccine / Q000276:immunology*; D008459:Measles virus / Q000276:immunology; D012372:ROC Curve; D012680:Sensitivity and Specificity; D013048:Specimen Handling / Q000379:methods; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D008458:Measles Vaccine